Aastrom to Present at 24th Annual ROTH Capital Conference
12 mars 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Webcast Alert: Aastrom to Report Fourth Quarter and Year-End 2011 Operating Results on Monday, March 12, 2012
09 mars 2012 11h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Completes $40 Million Financing
09 mars 2012 11h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T
29 févr. 2012 16h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences to Present at Piper Jaffray 23rd Annual Health Care Conference in New York City
22 nov. 2011 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Reports Positive 12-Month Results from the RESTORE-CLI Phase 2 Clinical Trial for Ixmyelocel-T in Patients with Critical Limb Ischemia
14 nov. 2011 11h15 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Hold Research and Development Day Review for Investors on November 17, 2011
11 nov. 2011 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Third Quarter 2011 Financial Results
08 nov. 2011 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to Feature Aastrom Biosciences
03 nov. 2011 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Final 12-Month Results From the Aastrom RESTORE-CLI Phase 2b Clinical Trial to be Presented at the American Heart Association Scientific Sessions 2011 on Monday, November 14, 2011
01 nov. 2011 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...